The first call was launched on February 6th, 2025, and closed June 30th, 2025, but was only open to sponsors of medical device clinical investigations.
What's new in this call?
- The pilot is now open to both medical device clinical investigations and IVD performance studies.
- Interested sponsors must submit an expression of interest using the official form and email it to SANTE-CA-CIPS@ec.europa.eu by 30 April 2026.
- The eligibility criteria are clarified: the study must be multinational (involving at least two participating Member States) and subject to authorisation under MDR Art 62(1) or IVDR Art 58(1-2).
- The Commission has published an updated list of participating Member States, along with practical and organisational details for sponsors.
- The pilot continues to support the development of the future mandatory EU coordinated assessment system, allowing sponsors early experience with harmonised processes
What does this mean for you?
This renewed call is highly relevant for sponsors planning multinational clinical investigations or IVD performance studies requiring authorisation. Whether stand-alone or linked to a clinical trial of a medicinal product, participation in the pilot enables:
- reduced administrative burden,
- more transparent and predictable interactions with competent authorities,
- simplified document handling, and
- a more harmonised EU authorisation process.
If you would like to assess whether your study could benefit from inclusion in the pilot, our consultants are available to support you. Please feel free to get in touch.
关于作者
MSc Biomedical Sciences · Business Unit Manager RA IVD & Representative Services
With over 20 years of experience in the diagnostics industry, Kirsten leads the IVD Regulatory Affairs business unit at QbD Group, guiding regulatory strategy and compliance across all IVDs with a focus on companion diagnostics.
Navigate Regulatory Complexity with Confidence
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。


